Home » Borsa Milano rises in the first session of April, Diasorin and Fineco excel

Borsa Milano rises in the first session of April, Diasorin and Fineco excel

by admin
Borsa Milano rises in the first session of April, Diasorin and Fineco excel
  1. Home ››
  2. News >>
  3. News Italy ››


FACEBOOK
TWITTER
LINKEDIN

Beginning of April with a prevalence of purchases in Piazza Affari. The Ftse Mib closed + 0.57% at 25,163 points on a day that is seeing Wall Street sailing close to parity. No surprises from the report on the labor market (+ 431,000 jobs in March, slightly below expectations) which remains solid, supporting the idea that the Fed could decide to make a series of rate hikes of 50bp each. until summer.

Among the individual stocks, the weakness of TIM is confirmed today, which marks -3.78% at € 0.3209 thanks to the fears that the KKR offer will not actually materialize. On the single network front, Tim and CDP could enter into negotiations shortly. In this regard, Il Messaggero reports that the CDP board of directors that met yesterday would not have discussed the single network issue as at the moment the PNRR races are still underway, with Tim and Open Fiber competing. However, according to press sources, an extraordinary Board of Directors of CDP could be held between 5 or 6 April to make a formal decision on the preliminary agreement with Tim.

STM was also bad today (-2.78%), while banks did well (+ 1.49% Unicredit, + 1.7% Bper and + 1.03% Intesa).

Among the best of the day stands Diasorin (+ 2.57%) which was included by Equita among its best picks by virtue of the quality of the stock in a market in structural growth (and less impacted by macro / cost inflation dynamics) and with a management team of primary standing. Among the best picks of Equita also Campari (+ 1.66%) and Fineco (+ 3.36%) make their entry.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy